Respiratory Inhalers Market Size
The global respiratory inhalers market reached USD 30.8 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 49.0 billion by 2030. the global respiratory inhalers market is expected to exhibit a CAGR of 6.1% during the forecast period (2023-2030). Respiratory inhalers are essential in the management and treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease (COPD), and others.
Inhalers are typically used to treat symptoms related to respiratory diseases such as wheezing, shortness of breath, coughing, and chest tightness. They aid to open up the airways and relieve breathing issues by providing bronchodilation. Individuals suffering from respiratory disorders might benefit greatly from quick and efficient symptom alleviation.
Furthermore, the respiratory inhalers market are driven by various factors like the rapidly increasing prevalence of the respiratory disorder, the increasing demand for treatment options for respiratory disorders and the accessibility of well-developed technologies, Also the increasing geriatric population, rising awareness regarding pulmonary diseases as well as increasing healthcare spending, Increasing use of fluoroscopy in pain management will also make sure high industry growth over the forecast period.
Market Scope
| Metrics | Details |
| CAGR | 6.1% |
| Size Available for Years | 2021-2030 |
| Forecast Period | 2023-2030 |
| Data Availability | Value (US$) |
| Segments Covered | Technology, Product, Appliction, End User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Infection Type Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
For More Insights Download Sample
Respiratory Inhalers Market Dynamics
Rapidly Increasing Prevalence of Respiratory Disorders
The rapidly increasing prevalence of respiratory diseases is one of the significant drivers that helps the respiratory inhalers market to grow during the forecast period. For instance, according to the WHO updated factsheet, Asthma, COPD, and pulmonary atrial hypertension are rising respiratory ailments, driving the market for respiratory inhalers. Where there were reported 455,000 asthma deaths in 2019, affecting 262 million people. COPD affects 200 million people, with 3.2 million deaths annually, making it the third-leading cause of death globally.
Increasing Usage of Combination Therapy
The growing use of combination therapies for asthma is increasing demand for respiratory inhalers like dry powder and soft mist inhalers due to their effective results in patients. These devices are becoming the best options for introducing combination drugs.
For instance, In Jan 2023. The FDA has approved the first combination of inhaled corticosteroids for asthma treatment in adults aged 18 and older. Albuterol and budesonide are combined to prevent and treat bronchoconstriction, making it the first in the US. This treatment relaxes muscles and reduces airway inflammation, lowering the risk of severe asthma attacks. It is the first product to contain an inhaled corticosteroid in the US.
High Cost of Inhalers
The high cost of inhalers is a significant concern for many individuals who rely on these devices to manage respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). As the cost of the smart inhalers is high the market growth will be hampered to a great extent as many patients in underdeveloped and developing nations may not be able to afford this equipment.
Respiratory Inhalers Market Segmentation Analysis
The global respiratory inhalers devices is segmented based on technology, product, application,end-user and region.
Dry Powder Inhalers from the Product Segment Accounted for Approximately 42.5% of the Respiratory Inhalers Devices Market Share
The dry powder inhalers from the product segment with around 42.5% is expected to dominate during the forecast period. A dry powdered inhalers (DPI) is an asthma therapy option for older children and teenagers. Using a dry powdered inhalers helps the medication to penetrate deep into the lungs. Unlike conventional inhalers that release a puff of medication, these inhalers hold the drug as a dry powder. This inhalers is triggered by breathing. The drug is only released when you take a deep, rapid breath into the inhalers. This is not the same as a metered dosage inhalers, which propels drugs into the lungs.
For instance,Glenmark Pharma has launched a Tiotropium Bromide Dry Powder Inhalers in the UK for treating chronic obstructive pulmonary disease (COPD), a long-term condition causing lung inflammation, damaged tissue, and narrowing of airways.
Source: DataM Intelligence Analysis (2023)
Global Respiratory Inhalers Market Geographical Share
North America Accounted for Approximately 38.6% of the Market Share in 2022
North America is estimated to hold about 38.6% of the total market share throughout the forecast period. For instance, according to the Asthma and Allergy Foundation of America's updated factsheet Asthma affects around 26 million people in the US, with Black adults having the highest rates. Females are more common than males, with 9.7% having asthma compared to 6.2%.
Asthma is a leading chronic disease in children, with 4.8 million under 18 having it. Non-Hispanic Black children are more than twice as likely to have asthma compared to non-Hispanic white children. Male children have a higher prevalence of asthma, with 7.3% having it compared to 5.6% of female children.
Source: DataM Intelligence Analysis (2023)
Respiratory Inhalers Market Major Companies
The major global players in the respiratory inhalers devices include Adherium Limited, AstraZeneca plc, Beximco Pharmaceuticals Ltd., Boehringer Ingelheim International GmbH, CHIESI Farmaceutici S.P.A, Cipla Inc, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., HELTMAN Medikal A.S, Koninklijke Philips N.V and others.
COVID-19 Impact
Russia-Ukraine Conflict Analysis
The Russia-Ukraine conflict is estimated to have a moderate impact on the global respiratory inhalers, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of devices is expected to have little influence over the global respiratory inhalers market growth over the forecast period.
By Technology
- Manually Operated Inhalers
- Digitally Operated Inhalers
By Product
- Dry Powder Inhalers
- Metered Dose Inhalers
- Nebulizers
By Application
- Asthma
- Chronic Obstructive Pulmonary Disease
- Pulmonary Atrial Hypertension
- Others
By End User
- Hospitals
- Respiratory Care Centers and Clinics
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Key Developments
- In June 2023, Lupin received USFDA approval for its Tiotropium Dry Powder Inhalers, a generic equivalent of Boehringer Ingelheim Pharmaceuticals' Spiriva HandiHaler. The FDA granted approval for the 18 mcg/capsule inhalers.
- On August 4 2022 Aptar Pharma has acquired the Orbital Dry Powder Inhalers (DPI) License, enabling the delivery of high doses of drugs like antibiotics to the lungs. This innovative platform, originally developed for the Pharmaxis cystic fibrosis drug Bronchitol, allows patients to inhale powder payloads of up to 400mg without reloading.
- In January 2023, Synergy Life Science developed Nebi, a portable, battery-operated nebulizer for various applications, making it the first of its kind in the consumer health and wellness market.
Why Purchase the Report?
- To visualize the global respiratory inhalers devices market segmentation based on technology, product, application, end user and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of respiratory inhalers devices market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global respiratory inhalers devices report would provide approximately 53 tables, 54 figures and 195 pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
Emerging Companies
